AHR and urinary bladder cancer: Amplifications of aryl hydrocarbon receptor (AHR) have been recently identified in bladder cancer [17], and its activation was also associated with grade, stage, and progression [18], confirming the protective role of its loss (100% of patients) observed in TGCA.